I
n the United States, more than 600,000 total knee replacements and 285,000 total hip replacements are performed each year. 1, 2 At Florida Hospital, a 4415 bed hospital system with 22 campuses in central Florida, surgeons perform more than 2100 primary total hip and knee replacements each year at the 7 campuses in the greater Orlando area. Perioperative pain management protocols, which include oral and parenteral analgesics, regional anesthetics, and sur- Between 2010 and 2011, a perioperative pain protocol for primary total hip and knee replacement at one Florida medical center replaced preoperative oral analgesics with intravenous methocarbamol and intravenous acetaminophen. This is a retrospective cohort study of 300 patients, with 150 patients using the new pain protocol and 150 patients using a 2008 pain protocol that did not include these medications. The 2 cohorts were similar in patient gender, age, and body mass index. Opioid consumption was evaluated for a period of 48 hours after incision and was divided into 3 separate time intervals, as well as total 48-hour consumption. Mean opiate use decreased signifi cantly from 2008 to 2011 in all time intervals and total consumption (7.5Ϯ3.4 mg to 6.1Ϯ3.0 mg; PϽ.01). Subgroup analysis suggested that changes to the hip protocol were responsible for decreased opioid use in the operating room and the postanesthesia care unit, and changes to the knee protocol were responsible for decreased opioid use on the hospital fl oor and total consumption. The difference between the 2 protocol groups was not due to differences in individual surgeon practice patterns. Physical therapy progress of knee fl exion, average walking distance, and maximum walking distance were signifi cantly improved. Hospital discharge was shorter in the 2011 group (4.0Ϯ1.1 days in 2008 group and 3.6Ϯ1.0 days in 2011 group). This study shows signifi cant improvement in patient care from 2008 to 2011 that is at least partially due to the change to the use of preoperative intravenous methocarbamol and intravenous acetaminophen.
48 hours of continuous regional anesthesia for postoperative pain management. By 2010, the use of postoperative opioids after total knee surgery decreased significantly, and patient-controlled analgesia delivery of intravenous hydromorphone was replaced with nursing administration of oral oxycodone plus acetaminophen or intravenous hydromorphone at patient request only. In addition, preoperative treatment with oral analgesics (a surgeon-ordered combination of 1 or more of celecoxib, oxycodone plus acetaminophen, or pregabalin) was replaced with intravenous methocarbamol (Robaxin Injection; Baxter Healthcare Corporation, Deerfi eld, Illinois). The goals with this medication were to reduce oral loading preoperatively and reduce recovery room discharge delays due to muscle spasm pain. At that time, no reports existed on the effectiveness of intravenous methocarbamol postoperatively for total joint surgery. Two studies of its use after breast augmentation had been performed, [3] [4] [5] but this medication was ignored by most of the anesthesia pain literature. 6 In 2011, intravenous acetaminophen (OFIRMEV; Cadence Pharmaceuticals, Inc., San Diego, California) was added to the protocol. Physicians and nursing staff had anecdotally reported that the combination of intravenous methocarbamol and intravenous acetaminophen improved the early postoperative recovery after total hip and knee replacement. Although intravenous acetaminophen had been studied for use in major orthopedic surgery, 7, 8 it had not been studied when added to a perioperative pain protocol that included long acting peripheral regional anesthetics and other intravenous adjuncts.
Our retrospective study compares a cohort of patients from 2011, who received preoperative intravenous methocarbamol and intravenous acetaminophen, with a cohort of patients using the 2008 pain protocol, who did not receive these medications. The outcome measures studied were opioid consumption, time to fi rst opioid rescue, VAS pain scores, physical therapy progress, and hospital discharge times. This was considered a pilot study to determine if a prospective, randomized, controlled clinical trial would likely show any benefi t from expanding the use of these 2 intravenous medications from 1 preoperative dose to regular dosing for the fi rst 48 hours.
MATERIALS AND METHODS
The Institutional Review Boards of Florida Hospital and the University of Central Florida approved this retrospective 2 cohort study with HIPAA and informed consent waivers for 300 patients. One hundred fi fty patients were included in the study group (using the 2011 protocol with preoperative intravenous methocarbamol and intravenous acetaminophen), and 150 patients in the control group (using the 2008 protocol without these 2 medications). The patient population was identifi ed from anesthesia billing records, including all patients from Florida Hospital Winter Park who had primary unilateral total knee arthroplasty (CPT 27447) or primary total hip arthroplasty (CPT 27130) between January 1, 2009, and October 12, 2011. Patients were grouped according to the perioperative pain protocol and excluded patients from the 2010 protocol who received intravenous methocarbamol but not intravenous acetaminophen.
Within each protocol group, patients were also grouped fi rst by surgeon (from greatest to least surgical volume), next by anesthesiologist (from greatest to least volume), and fi nally by date of surgery (in reverse chronologic order). Since the total knee arthroplasty volume at Florida Hospital Winter Park (700 in 2011) is approximately twice that of total hip arthroplasty volume (375 in 2011), the team decided, a priori, to include 100 knees and 50 hip patients from each protocol group. This made it possible to limit the study to 2 surgeons performing knees (50 using the 2011 study protocol and 50 using the 2008 control protocol each) and 2 surgeons performing hips (25 using the 2011 study protocol and 25 using the 2008 control protocol each). In total, the study included patients from 3 surgeons, because the second most prolifi c knee surgeon was also the second most prolifi c hip surgeon. More emphasis was placed on limiting the number of surgeons rather than anesthesiologists, because the number of patient-care items left to the discretion of the surgeon is greater than those left to the discretion of the anesthesiologist. In addition, the team wanted to determine whether those items left to surgical discretion, such as intraoperative surgical site injections and perioperative analgesic adjunct selection, infl uenced primary outcome differences.
Patients were evaluated from 2011 (study) and 2008 (control) protocol groups in the order described above and included those patients, between the ages of 18 and 85, who had an American Society of Anesthesiologists (ASA) physical status of 1 to 3. Patients were excluded if they had chronic pain with patient reported opioid use 1 month preoperatively; had taken centrally acting muscle relaxants 24-hours preoperatively; received a regional anesthesia procedure for postoperative pain control (other than a femoral nerve sheath catheter for knees or fascia iliaca block for hips); did not receive both of the study medications; and if there was a notable surgical complication as defi ned by the surgeon's operative report. Data was collected for 300 patients. During the data analysis phase, 1 total hip patient in the 2008 protocol group, whose opioid consumption exceeded 5 standard deviations above the mean, was also excluded from analysis, based on a history of chronic pain that had been missed in the initial assessment. Thus, 299 patients with a primary total knee or total hip replacement were included in the study.
For the study time periods, the surgical incision was defi ned as time zero.
All outcome data for the fi rst 48 hours after surgical incision was placed into 1 of 10 distinct time periods: intraoperative OR (incision time to time of admission to the postanesthesia care unit), postanesthesia care unit PACU (recovery room admission time to discharge time), and 8 6-hour hospital FLOOR intervals with interval 1 starting at PACU discharge and ending 6 hours after incision time. Any opioids given prior to surgical incision (preoperative or for induction of anesthesia) and included in surgical site injections were excluded. All data were obtained from electronic medical records including scanned anesthesia and nursing notes, dictated operative reports, and electronically entered nursing, pharmacy, and physical therapy notes.
The primary study endpoint was opioid consumption, which was documented in the electronic medical record, and all opioid medication was converted to hydromorphone equivalent milligrams ( Table 1 ). The secondary study endpoints were: VAS pain scores (recorded by nursing staff at regular intervals and prior to administration of PRN opioids); rescue time (in minutes from incision to fi rst request for opioid medication); physical therapy progress (range of motion after total knee in degrees of fl exion and extension, and ambulation in feet after both total hip and total knee) recorded by a physical therapist once or twice daily; PACU discharge time (in minutes from time of arrival to the time that PACU discharge criteria was met); and hospital discharge time (in days from time of incision to time offi cially recorded as end of hospital admission).
Statistical analysis used a chi-square test for each categorical variable (gender and ASA class) and considered noncategorical variables to be continuous. The team then evaluated noncategorical variables using either parametric or nonparametric tests depending on whether the data were found to be normally or nonnormally distributed. Parametric tests included an independent 2-sample t test for the primary group (protocol) comparisons and analysis of variance (ANOVA) for the multiple subgroup comparisons. The 
RESULTS
The patients in the 2 protocol cohorts showed similar demographic data for gender, age, and body mass index (BMI), but there was a signifi cantly greater number of ASA 3 (and fewer ASA 1) patients in the 2008 protocol group (Table 2) .
Four time intervals contained enough data to be evaluated for the primary outcome, opiate consumption: OR, PACU, FLOOR, and TOTAL (Table 3 ). The FLOOR period combined the 8 6-hour FLOOR intervals (as described above) into 1, a necessary adjustment due to sporadic FLOOR data. The TOTAL period combined all data for the 48-hour period starting with incision time.
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Our patient population demonstrated a non-normally distributed opioid use that was heavily skewed to the left with the median much greater than the mean in all time periods. Even with patients in both protocol groups requiring minimal opioids in the OR and PACU (Figure 1 , for the OR), nonparametric analysis showed signifi cant reduction of opioid use in the 2011 protocol group in all time periods (Figure 2) .
The results were also analyzed focusing on surgery type (hip or knee) and surgeon (Table 3) . For surgery type, data proved adequate for all time periods for both hip and knee surgeries and showed the same skew to the left as the full protocol groups, necessitating a nonparametric approach for this analysis as well. The 2011 protocol group demonstrated significantly reduced opioid use in the OR and PACU time periods after hip surgery but not knee surgery. There was signifi cantly reduced opioid use on the FLOOR and Continued from page 27 TOTAL in the knee surgery group but not the hip surgery group. Examining the individual surgeons (identifi ed only as surgeons 1, 2, and 3), FLOOR and TOTAL opiate use were normally distributed data and ANOVA was used to determine if changes in opioid use (FLOOR and TO-TAL) from the 2008 protocol to the 2011 protocol could be accounted for by those items left to surgeon discretion (Table 3 ). All subgroups showed reduced opioid use from the 2008 protocol to the 2011 protocol, except for increased FLOOR opioid use for surgeon 1, hip (Figures 3, 4) . ANOVA analysis showed that differences in opioid use from the 2 protocols cannot be accounted for (statistically) by differences among the surgeons. This assessment is tempered by a positive Levene's test of equality of error variances for the hip surgeon population groups. A positive Levene's test means that the 2 hip surgeon population groups have such different statistical characteristics that ANOVA may not be valid. Examining secondary outcomes (Table  4) , the average pain intensity increased signifi cantly from the 2008 protocol to the 2011 protocol. Of the 10 time intervals of the study, only time interval 5 (from 24 to 30 hours post-incision) had enough data points for separate evaluation. This showed no signifi cant difference between pain intensity scores in this time interval. In addition, no signifi cant differences in rescue time were found. All physical therapy metrics, except for knee extension, improved in the 2011 protocol group. PACU discharge times were unchanged. There was approximately a half-day reduction in hospital length of stay between the patients in the 2008 and 2011 protocols.
DISCUSSION
This retrospective cohort study showed that patient care for primary hip and knee replacement at Florida Hospital Winter Park improved from the 2008 protocol to the 2011 protocol. Opioid consumption decreased signifi cantly, physical therapy progress accelerated, and length of hospital stay decreased. The study was designed to isolate, as much as possible, the infl uence of adding a single, preoperative dose of intravenous methocarbamol and intravenous acetaminophen on these outcomes. However, due to the retrospective nature of the study, it was not possible to eliminate all confounding variables, including differences in patient populations, planned changes in the protocols other than the study medications, and changes in surgeon practices.
The 2008 protocol group had signifi cantly more ASA 3 patients than the 2011 group (33% vs 25%, P=.011). This factor could possibly account for an increased length of stay in the 2008 group. This 8% difference, although statistically signifi cant, would not impact a power analysis or design a future randomized, controlled clinical trial.
In addition to adding a single, preoperative dose of intravenous methocarbamol and intravenous acetaminophen, other changes to the perioperative pain protocols occurred from the 2008 group to the 2011 group, including type of anesthesia, spinal morphine, and fascia iliaca blocks. In the 2008 protocol group, 80% of the patients received general anesthesia (Table 5 ). In the 2011 protocol, 80% of the patients received spinal anesthesia. The expected result of spinal anesthesia is less or no pain in the early postoperative period and a shift in opioid use from intraoperative loading to post-PACU (FLOOR) dosing. The (Table 3 ) and probably to the slight (insignifi cant) increase in opioid use on the fl oor. Overall, the TOTAL opiate use after hip surgery was numerically, but not statistically less (P=.074). In the 2008 total hip protocol, 33% of patients (all from surgeon 2) also received spinal morphine, but this increased to 80% of patients in the 2011 hip protocol (from both surgeons). The expected benefi t is 6 to 12 hours of postoperative pain relief. None of the knee patients received spinal morphine. Ultrasound-guided fascia iliaca blocks were also added to all patients in the 2011 protocol for total hip surgery, which may provide 12 hours of postoperative pain relief. We are not able to determine if the increased use of spinal morphine or fascia iliaca blocks to the 2011 THA protocol contributed to the fi ndings. It is possible that a statistically signifi cant increase in FLOOR opioid use was averted by these techniques.
Other changes in the use of patientcontrolled analgesia, preoperative oral analgesics, and surgical site injections may have infl uenced the results. Ten months after initiating the 2008 protocol, most total knee patients who received spinal anesthesia and a femoral nerve catheter controlled their postoperative pain with only PRN oral opioids. The patientcontrolled analgesia for total knee surgery postoperatively was phased out over the next year. In the 2008 protocol group, 33% of patients (who had their surgery in 2009 and early 2010) received a patientcontrolled analgesia, and with the 2011 protocol, no patients (except chronic pain patients) received a patient-controlled analgesia. This was also phased out for total hip patients, with 80% receiving patient-controlled analgesias in the 2008 protocol group and only 24% receiving patient-controlled analgesias in the 2011 protocol group (Table 6 ). There was a signifi cant reduction in late opiate use (FLOOR and TOTAL) and a concomitant increase in average pain scores (Table 4) . This may be related to eliminating the patient-controlled analgesia. The presence of a patient-controlled analgesia is an independent (second only to pain itself) driver of opioid consumption and its elimination will decrease opioid use without signifi cantly changing patient satisfaction. Thus, we were surprised to see a 12% increase in pain scores and are uncertain if the increase in average pain scores from 4.9 to 5.5 is accompanied with reduced patient satisfaction.
In the 2008 protocol, both knee surgeons (surgeon 2 and surgeon 3), routinely ordered preoperative and postoperative oral analgesics, including celecoxib and a 
